Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms [PDF]
Frontiers in Immunology, 2021 BackgroundAnti-interleukin (IL)-23 agents are widely used for autoimmune disease treatment; however, the safety and risks of specific symptoms have not been systematically assessed.ObjectivesThe aim of this study was to summarize the characteristics and ...
Yi Ru +26 more
doaj +4 more sources
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis [PDF]
Drug Design, Development and Therapy, 2018 Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has been primarily developed for use in moderate-to ...
Isabel Haugh +3 more
europepmc +7 more sources
Rare pediatric Saccharomyces cerevisiae fungemia with neutralizing anti-IL-23 autoantibodies: a case report [PDF]
BMC PediatricsAnti-IL-23 autoantibodies are associated with severe, persistent opportunistic infections. We described the first pediatric case of Saccharomyces cerevisiae fungemia with high anti-IL-23 autoantibodies, which was successfully treated using the novel ...
Yajuan Zhou +3 more
doaj +2 more sources
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients [PDF]
Frontiers in ImmunologyIntroductionPsoriasis is a chronic immune-mediated inflammatory skin disorder, frequently associated with comorbidities such as obesity, which can exacerbate its severity and hinder treatment efficacy. Psoriasis pathogenesis involves complex interactions
Roberta Belli +21 more
doaj +2 more sources
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. [PDF]
Drug design, development and therapy, 2019 The approval of guselkumab marks the entry of the IL-23 inhibitor class into the therapeutic armamentarium for patients with moderate-to-severe plaque psoriasis. This class specifically targets the upstream portion of the type 17 helper T (Th17) axis, which has been implicated as a key driver of the abnormal inflammatory state observed in psoriasis ...
Yang,Eric J +3 more
europepmc +6 more sources
Intraperitoneal administration of the anti-IL-23 antibody prevents the establishment of intestinal nematodes in mice [PDF]
Scientific Reports, 2018 AbstractPrevious studies have established that an increased Th-9 response creates a hostile environment for nematode parasites. Given that IL-23, a cytokine required for maintenance of the IL-17–secreting phenotype, has inhibitory effects on IL-9 production, we hypothesized that reducing circulating IL-23 by treatment with anti-IL-23 antibodies would ...
M. Gomez-Samblas +7 more
openaire +6 more sources
Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study [PDF]
Dermatology and TherapyPsoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and therapeutic targets.This study aimed to investigate changes in circulating miRNAs in psoriasis patients ...
Diotallevi, Federico +11 more
openaire +6 more sources
Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies [PDF]
Therapeutic Advances in GastroenterologyInflammatory bowel diseases (IBD) and psoriasis are chronic inflammatory conditions belonging to the heterogeneous group of immune-mediated inflammatory diseases (IMIDs).
Cristina Bezzio +9 more
doaj +2 more sources
Linear psoriasis unresponsive to multiple biological therapies (anti-TNF, anti-IL-12/23, and anti-IL-23): a case report [PDF]
Anais Brasileiros de DermatologiaSonia Romero-Romero +3 more
doaj +2 more sources
Safety and Efficacy of Anti–IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis
JAMA DermatologyImportancePsoriasis is a chronic, immune-mediated skin disease with an unmet need for biologic treatment options.ObjectiveTo assess the safety, pharmacokinetics, and efficacy of QX004N in healthy individuals and patients with moderate to severe plaque psoriasis in China.Design, Setting, and ParticipantsThis randomized clinical trial was composed of 2 ...
Xiaojiao, Li +13 more
europepmc +4 more sources